These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 23941127)

  • 1. Evaluation of the need for routine clinical testing of PALB2 c.1592delT mutation in BRCA negative Northern Finnish breast cancer families.
    Haanpää M; Pylkäs K; Moilanen JS; Winqvist R
    BMC Med Genet; 2013 Aug; 14():82. PubMed ID: 23941127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterozygous PALB2 c.1592delT mutation channels DNA double-strand break repair into error-prone pathways in breast cancer patients.
    Obermeier K; Sachsenweger J; Friedl TW; Pospiech H; Winqvist R; Wiesmüller L
    Oncogene; 2016 Jul; 35(29):3796-806. PubMed ID: 26640152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of the PALB2 c.2323C>T [p.Q775X] founder mutation in well-defined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent.
    Tischkowitz M; Sabbaghian N; Hamel N; Pouchet C; Foulkes WD; Mes-Masson AM; Provencher DM; Tonin PN
    BMC Med Genet; 2013 Jan; 14():5. PubMed ID: 23302520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families.
    Pylkäs K; Erkko H; Nikkilä J; Sólyom S; Winqvist R
    BMC Cancer; 2008 May; 8():146. PubMed ID: 18501021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence against PALB2 involvement in Icelandic breast cancer susceptibility.
    Gunnarsson H; Arason A; Gillanders EM; Agnarsson BA; Johannesdottir G; Johannsson OT; Barkardottir RB
    J Negat Results Biomed; 2008 Jul; 7():5. PubMed ID: 18637200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Penetrance analysis of the PALB2 c.1592delT founder mutation.
    Erkko H; Dowty JG; Nikkilä J; Syrjäkoski K; Mannermaa A; Pylkäs K; Southey MC; Holli K; Kallioniemi A; Jukkola-Vuorinen A; Kataja V; Kosma VM; Xia B; Livingston DM; Winqvist R; Hopper JL
    Clin Cancer Res; 2008 Jul; 14(14):4667-71. PubMed ID: 18628482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A clinically structured and partnered approach to genetic testing in Trinidadian women with breast cancer and their families.
    Donenberg T; George S; Ali J; Bravo G; Hernandez K; Sookar N; Ashing KT; Narod SA; Akbari MR; Hurley J
    Breast Cancer Res Treat; 2019 Apr; 174(2):469-477. PubMed ID: 30515680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A recurrent mutation in PALB2 in Finnish cancer families.
    Erkko H; Xia B; Nikkilä J; Schleutker J; Syrjäkoski K; Mannermaa A; Kallioniemi A; Pylkäs K; Karppinen SM; Rapakko K; Miron A; Sheng Q; Li G; Mattila H; Bell DW; Haber DA; Grip M; Reiman M; Jukkola-Vuorinen A; Mustonen A; Kere J; Aaltonen LA; Kosma VM; Kataja V; Soini Y; Drapkin RI; Livingston DM; Winqvist R
    Nature; 2007 Mar; 446(7133):316-9. PubMed ID: 17287723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A PALB2 germline mutation associated with hereditary breast cancer in Italy.
    Papi L; Putignano AL; Congregati C; Piaceri I; Zanna I; Sera F; Morrone D; Genuardi M; Palli D
    Fam Cancer; 2010 Jun; 9(2):181-5. PubMed ID: 19763884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PALB2 analysis in BRCA2-like families.
    Adank MA; van Mil SE; Gille JJ; Waisfisz Q; Meijers-Heijboer H
    Breast Cancer Res Treat; 2011 Jun; 127(2):357-62. PubMed ID: 20582465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of PALB2 gene in BRCA1/BRCA2 negative Spanish hereditary breast/ovarian cancer families with pancreatic cancer cases.
    Blanco A; de la Hoya M; Osorio A; Diez O; Miramar MD; Infante M; Martinez-Bouzas C; Torres A; Lasa A; Llort G; Brunet J; Graña B; Perez Segura P; Garcia MJ; Gutiérrez-Enríquez S; Carracedo Á; Tejada MI; Velasco EA; Calvo MT; Balmaña J; Benitez J; Caldés T; Vega A
    PLoS One; 2013; 8(7):e67538. PubMed ID: 23935836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy.
    Ghiorzo P; Pensotti V; Fornarini G; Sciallero S; Battistuzzi L; Belli F; Bonelli L; Borgonovo G; Bruno W; Gozza A; Gargiulo S; Mastracci L; Nasti S; Palmieri G; Papadia F; Pastorino L; Russo A; Savarino V; Varesco L; Bernard L; Bianchi Scarrà G;
    Fam Cancer; 2012 Mar; 11(1):41-7. PubMed ID: 21989927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PALB2 variants in hereditary and unselected Finnish prostate cancer cases.
    Pakkanen S; Wahlfors T; Siltanen S; Patrikainen M; Matikainen MP; Tammela TL; Schleutker J
    J Negat Results Biomed; 2009 Dec; 8():12. PubMed ID: 20003494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype.
    Heikkinen T; Kärkkäinen H; Aaltonen K; Milne RL; Heikkilä P; Aittomäki K; Blomqvist C; Nevanlinna H
    Clin Cancer Res; 2009 May; 15(9):3214-22. PubMed ID: 19383810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.
    Couch FJ; Shimelis H; Hu C; Hart SN; Polley EC; Na J; Hallberg E; Moore R; Thomas A; Lilyquist J; Feng B; McFarland R; Pesaran T; Huether R; LaDuca H; Chao EC; Goldgar DE; Dolinsky JS
    JAMA Oncol; 2017 Sep; 3(9):1190-1196. PubMed ID: 28418444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PALB2 mutations in BRCA1/2-mutation negative breast and ovarian cancer patients from Poland.
    Kluska A; Balabas A; Piatkowska M; Czarny K; Paczkowska K; Nowakowska D; Mikula M; Ostrowski J
    BMC Med Genomics; 2017 Mar; 10(1):14. PubMed ID: 28279176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two PALB2 germline mutations found in both BRCA1+ and BRCAx familial breast cancer.
    Downs B; Kim YC; Xiao F; Snyder C; Chen P; Fleissner EA; Becirovic D; Wen H; Sherman S; Cowan KH; Lynch HT; Wang SM
    Breast Cancer Res Treat; 2015 May; 151(1):219-24. PubMed ID: 25833210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer.
    Francies FZ; Wainstein T; De Leeneer K; Cairns A; Murdoch M; Nietz S; Cubasch H; Poppe B; Van Maerken T; Crombez B; Coene I; Kerr R; Slabbert JP; Vral A; Krause A; Baeyens A; Claes KB
    BMC Cancer; 2015 Nov; 15():912. PubMed ID: 26577449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole-exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene.
    Silvestri V; Zelli V; Valentini V; Rizzolo P; Navazio AS; Coppa A; Agata S; Oliani C; Barana D; Castrignanò T; Viel A; Russo A; Tibiletti MG; Zanna I; Masala G; Cortesi L; Manoukian S; Azzollini J; Peissel B; Bonanni B; Peterlongo P; Radice P; Palli D; Giannini G; Chillemi G; Montagna M; Ottini L
    Cancer; 2017 Jan; 123(2):210-218. PubMed ID: 27648926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.